KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 14 years of Other Gross PP&E Adjustments data on record, last reported at $7.2 billion in Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 7.33% year-over-year to $7.2 billion; the TTM value through Dec 2025 reached $7.2 billion, up 7.33%, while the annual FY2025 figure was $7.2 billion, 7.33% up from the prior year.
  • Other Gross PP&E Adjustments reached $7.2 billion in Q4 2025 per REGN's latest filing, up from $6.7 billion in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $7.2 billion in Q4 2025 and bottomed at -$15.6 million in Q3 2022.
  • Average Other Gross PP&E Adjustments over 4 years is $4.8 billion, with a median of $5.5 billion recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: grew 20.83% in 2024, then rose 7.33% in 2025.
  • A 4-year view of Other Gross PP&E Adjustments shows it stood at $4.8 billion in 2022, then grew by 14.71% to $5.5 billion in 2023, then grew by 20.83% to $6.7 billion in 2024, then increased by 7.33% to $7.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $7.2 billion in Q4 2025, $6.7 billion in Q4 2024, and $5.5 billion in Q4 2023.